« Back
Home /
Cirtuvivint

Cirtuvivint

Item no.	HY-137435-50mg
Manufacturer	MedChem Express
CASRN	2143917-62-6
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	98.28
Citations	[1]Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197.
Smiles	O=C(C1=CC(N2CCN(CC2)C)=NC=C1)NC3=NC=C4C=CC(C5=CN(C)N=C5)=CC4=C3
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	SM08502
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	427.50
Product Description	Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 12.5 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-137435-50mg-safety-datasheet.pdf